HealthTech and MedTech M&A 2026 Valuation Multipliers

The global healthcare technology and medical technology sectors have transitioned into a definitive era of disciplined industrial maturity as of the first half of 2026. This period, characterised as the emergence of HealthTech 2.0, represents a structural shift from the speculative, volume-driven dealmaking of the pandemic era toward high-value, transformative transactions grounded in fundamental business metrics. 
  
In this new phase, valuation is no longer merely a reflection of prospective market capture; instead, it is predicated on a company’s deep integration into clinical pathways, its regulatory fortitude under a maturing global framework and its capacity to deliver a sustainable, measurable return on investment to health systems facing unprecedented fiscal constraints. 
  
As 2026 unfolds, the market is witnessing a selective recovery where high-quality assets with defensible moats command premium multiples, while those lacking operational leverage or regulatory readiness face significant compression.

To read our full report please click here https://www.healthcare.digital/single-post/healthtech-and-medtech-m-a-2026-valuation-multipliers